Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2021-09-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于参加湖南辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company's participation in an investor online reception day event organized by regulatory and industry bodies. It includes details about the event date, platform, and encourages investor participation. There is no financial data, no report attached or referenced as being published, and no mention of voting results, management changes, or other specific filings. The document is informational and relates to investor relations activities but does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings with certifications. Given its nature and length (573 characters), it is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2021-09-17 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2021 年半年度报告全文" which translates to "2021 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, business overview, risk factors, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2021 to June 30, 2021, which is a half-year period, consistent with an interim report. The document is lengthy (15,000 characters) and includes actual financial statements and substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-27 Chinese
2021年半年度募集资金存放和使用情况的专项报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2021年半年度募集资金存放和使用情况的专项报告" which translates to "2021 Half-Year Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their deposit, usage, management, and investment projects related to the raised funds. It includes detailed financial figures and explanations about the use of funds during the half-year period ending June 30, 2021. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, specifically a half-year report. This matches the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a detailed report on the use of capital raised during the half-year period. Therefore, the correct classification is IR with high confidence. H1 2021
2021-08-27 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021 年半年度报告摘要' which translates to '2021 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. The length is 2694 characters, which is relatively short, but the content includes substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but contains actual financial figures and performance metrics for the half-year period. H1 2021
2021-08-27 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the third meeting of the ninth Supervisory Board of Qidi Pharmaceutical Group Co., Ltd. It includes approval of the 2021 semi-annual report, a special report on the use of raised funds, and an accounting policy change. The document is short (868 characters) and primarily reports on meeting decisions and approvals rather than containing the full semi-annual report or detailed financial data. It is not the report itself but an announcement of meeting resolutions and approvals related to financial reports and company governance. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-08-27 Chinese
关于拟注销部分全资子公司的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the planned cancellation (注销) of two wholly-owned subsidiaries. It includes details about the subsidiaries, their financials, reasons for cancellation, and the impact on the company. The document references a board meeting resolution approving the cancellation. There are no comprehensive financial statements or detailed financial performance data typical of an annual or interim report. The document is relatively short (2224 characters) and serves as a formal announcement of a corporate action rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory certification or officer attestation. The content aligns with a corporate announcement about a structural change, which is best classified under Regulatory Filings (RNS) as it does not fit more specific categories like Board/Management Information (MANG) which usually covers changes in board or senior management, or Capital/Financing Update (CAP). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-08-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.